Cholesteryl ester transfer protein (CETP) facilitates exchange of triglycerides and cholesteryl ester between high-density lipoprotein (HDL) and apolipoprotein B100-containing lipoproteins. Evidence from genetic studies that variants in the CETP gene were associated with higher blood HDL cholesterol, lower low-density lipoprotein cholesterol, and lower risk of coronary heart disease suggested that pharmacological inhibition of CETP may be beneficial. To date, 4 CETP inhibitors have entered phase 3 cardiovascular outcome trials. Torcetrapib was withdrawn due to unanticipated off-target effects that increased risk of death, and major trials of dalcetrapib and evacetrapib were terminated early for futility. In the 30,000-patient REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification) trial, anacetrapib doubled HDL cholesterol, reduced non-HDL cholesterol by 17 mg/dl (0.44 mmol/l), and reduced major vascular events by 9% over 4 years, but anaceptrapib was found to accumulate in adipose tissue, and regulatory approval is not being sought. Therefore, despite considerable initial promise, CETP inhibition provides insufficient cardiovascular benefit for routine use. (J Am Coll Cardiol 2019;73:477-87)
However, other studies have reached different conclusions, namely that either terminal (N or C) may bind to HDL and that a ternary structure and the presence of a tunnel is not necessarily required to explain CETP's function (4) .
EVIDENCE FROM GENETIC STUDIES THAT CETP IS CAUSALLY RELATED TO CARDIOVASCULAR DISEASE GENOME-WIDE ASSOCIATION STUDIES OF CETP, BLOOD LIPIDS, AND CORONARY HEART DISEASE.
The CETP gene is located on chromosome 16 and consists of w22 kilo base pairs with 16 exons.
Genome-wide association studies (GWAS) (5,6) of blood lipids measured in >100,000 individuals have identified rs3764261 in CETP to be associated with higher HDL and total cholesterol, and lower LDL cholesterol and TG, all at p # 2 Â 10 À25 . Furthermore, GWAS of 42,335 individuals with coronary heart disease (CHD) and 78,240 control subjects identified a variant in CETP (rs1800775) associated with higher risk of CHD (p ¼ 9.8 Â 10 À9 ) (7) , and also with lower HDL-C, higher LDL-C, and higher TG. OR ¼ odds ratio; PCSK9 ¼ Proprotein Convertase Subtilisin/Kexin type 9; other abbreviations as in Figure 1 .
Armitage et al. The primary outcome was also significantly more common among those allocated torcetrapib (6.2% vs. Armitage et al. There was no effect on BP, and no safety concerns emerged over 18 months. were eligible for the DEFINE 2-year extension study to assess longer-term safety and lipid effects (34) .
Armitage et al. Tables 1 and 2 . Armitage et al. By contrast, both non-HDL-C and apolipoprotein B100 appear to provide more informative measures.
Data in Table 2 demonstrate the modest reductions in apolipoprotein B100 from CETP inhibition compared with the substantially larger estimated reductions in calculated or directly measured LDL-C, a discrepancy also detected in a recent genetic study (13) . This underestimation appears less important at elevated LDL-C levels-in the REALIZE trial conducted in patients with familial hypercholesteremia, similar results for change in LDL-C were obtained by
Friedewald equation, direct assay, and beta quantification (40).
FUTURE PERSPECTIVES
Compared with routinely used nonstatin LDL-C lowering oral agents (such as ezetimibe), anaceptrapib is comparable in terms of lipid-modifying efficacy and safety (Table 3) . However, it was recently announced that Merck will not pursue regulatory 
